2 Rock-Solid Coronavirus Treatment Stocks to Buy Right Now

COVID-19 probably isn't going to be a passing fad. Despite the very real possibility that one or more vaccines will be approved in record time, clinicians still expect the viral illness to persist as a fairly common seasonal ailment over the current decade. Vaccines, after all, are highly unlikely to be 100% effective. Furthermore, the virus is expected to mutate in a manner that degrades the effectiveness of both first-generation vaccines and background immunity from prior infections over time.

What this all means is that COVID-19 treatments will likely be a key new product category within the world of biopharma for a long time to come. That being said, this niche area within the broader biopharmaceutical landscape is fraught with risk for a variety of reasons.

Image source: Getty Images.

Source Fool.com